Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10283044" target="_blank" >RIV/00216208:11110/14:10283044 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/14:00075327 RIV/00216208:11130/14:10283044 RIV/61989592:15110/14:33149138 RIV/00064203:_____/14:10283044 RIV/00064190:_____/14:#0000837
Result on the web
<a href="http://dx.doi.org/10.1186/1471-230X-14-53" target="_blank" >http://dx.doi.org/10.1186/1471-230X-14-53</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1186/1471-230X-14-53" target="_blank" >10.1186/1471-230X-14-53</a>
Alternative languages
Result language
angličtina
Original language name
Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry
Original language description
Background: Patients aged 65 years and older represent the majority of patients with metastatic colorectal cancer (mCRC). However, this patient population is often underrepresented in clinical trials and probably undertreated in the clinical practice. Methods: We have analysed the outcomes of 3,187 mCRC patients treated with first-line bevacizumab based on data from the Czech national registry of mCRC patients aiming to compare the treatment efficacy and safety according to the age categories. Results:In total, 2,126 (66.7%), 932 (29.2%), and 129 (4.0%) patients were aged < 65 years, 65 to 75 years, and 75+ years, respectively. Median progression-free survival (PFS) was 11.4, 11.3, and 11.8 months for patients aged < 65 years, 65 to 75 years, and 75+years, respectively (p = 0.94). Median overall survival (OS) was 26.9, 27.5, and 25.1 months for patients aged < 65 years, 65 to 75 years, and 75+ years, respectively (p = 0.73). Using multivariable Cox model for both PFS and OS, the pati
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
BMC Gastroenterology
ISSN
1471-230X
e-ISSN
—
Volume of the periodical
14
Issue of the periodical within the volume
March
Country of publishing house
GB - UNITED KINGDOM
Number of pages
8
Pages from-to
—
UT code for WoS article
000334417600002
EID of the result in the Scopus database
—